2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

Conclusion
A standard of care has been established for patients with
newly diagnosed glioblastoma on the basis of level 1 evidence
for a randomized clinical trial. Current investigations
are exploring agents to add to the established chemoradiation
regimen that would augment activity without a marked
increase in toxicity. Many of these trials are also including
molecular characterization of the tumors in an effort to
define patient subpopulations likely to benefit (or not benefit)
from the new regimen, thereby enhancing the risk to
benefit for individual patients.
Author’s Disclosure of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Mark R. Gilbert Abbott
Laboratories;
Genentech;
GlaxoSmithKline;
Merck
1. 2005-2006 Statistical Report: Primary Brain Tumors in the United
States Statistical Report, 1998-2002 (Years Data Collected). Hinsdale, IL:
Central Brain Tumor Registry of the United States; 2006.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med.
2008;359:492-507.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas.
N Engl J Med. 2009;360:765-773.
4. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of
progression-free and overall survival in patients with newly diagnosed
glioblastoma: a prospective translational study of the German Glioma Network.
J Clin Oncol. 2009;27:5743-5750.
5. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis
of prognostic factors in three Radiation Therapy Oncology Group malignant
glioma trials. J Natl Cancer Inst. 1993;85:704-710.
6. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG
island methylator phenotype that defines a distinct subgroup of glioma.
Cancer Cell 17:510-522.
7. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome
in glioblastoma. Neuro Oncol. 2010;12:49-57.
8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit
from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
9. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of
radiotherapy and nitrosoureas for the treatment of malignant glioma after
surgery. N Engl J Med. 1980;303:1323-1329.
10. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic
review and meta-analysis of individual patient data from 12 randomised
trials. Lancet. 2002;359:1011-1018.
11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.
2005;352:987-996.
12. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on survival
in glioblastoma in a randomised phase III study: 5-year analysis of the
EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466
13. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6alkylguanine-DNA
alkyltransferase activity with protracted temozolomide
schedules. Br J Cancer. 2003;88:1004-1011.
14. Gilbert MR, Wang M, Aldape K, et al. RTOG 0525: a randomized phase
III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense
(dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 2011;29
(suppl; abstr 141s).
15. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib
plus temozolomide during and after radiation therapy in patients with newly
diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:
579-584.
16. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly
116
A similar standard does not currently exist for recurrent
glioblastoma, although antiangiogenic agents particularly
bevacizumab, demonstrate tumor response and tumor control
although this is often short-lived and to date, there are
no salvage regimens after bevacizumab failure. Given the
marked molecular heterogeneity of recurrent glioblastoma,
future advances will likely require a major initiative to
perform clinical trials encompassing correlations or patient
selection on the basis of tumor characteristics. This initiative
will require both an increase in resource allocation and
a widespread collaborative effort to be successful.
Stock
Ownership Honoraria
REFERENCES
Genentech;
Merck
Research
Funding
Genentech;
Merck
Expert
Testimony
MARK R. GILBERT
Other
Remuneration
diagnosed glioblastoma treated with radiation and temozolomide in research
studies in the United States. Clin Cancer Res. 2010;16:2443-2449.
17. Stupp R, Goldbrunner B, Neyns B, et al. Phase I/IIa trial of cilengitide
(EMD121974) and temozolomide with concomitant radiotherapy, followed
by temozolomide and cilengitide maintenance therapy in patients (pts) with
newly diagnosed glioblastoma (GBM). J Clin Oncol. 2007;25 (suppl; abstr
2000).
18. Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a
prognostic marker for improved 6-month progression-free survival or overall
survival for patients with recurrent glioblastoma? Neuro Oncol. 2011;13:
1118-1124.
19. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of
safety and efficacy of intraoperative controlled delivery by biodegradable
polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor
Treatment Group. Lancet. 1995;345:1008-1012.
20. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery
of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a
report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin
Oncol. 2007;25:837-844.
21. Anderson RC, Elder JB, Brown MD, et al. Changes in the immunologic
phenotype of human malignant glioma cells after passaging in vitro. Clin
Immunol. 2002;102:84-95.
22. Rainov NG. A phase III clinical evaluation of herpes simplex virus type
1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical
resection and radiation in adults with previously untreated glioblastoma
multiforme. Hum Gene Ther. 2000;11:2389-2401.
23. Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus:
preclinical and clinical studies in patients with human malignant gliomas.
Curr Gene Ther. 2009;9:422-427.
24. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens
for the treatment of glioma. Neuro Oncol. 2009;11:69-79.
25. Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in
recurrent malignant glioma by using a continuous temozolomide schedule:
the “rescue” approach. Cancer. 2008;113:2152-2157.
26. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas
during temozolomide therapy and mediate temozolomide resistance. Clin
Cancer Res. 2009;15:4622-4629.
27. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of
enzastaurin compared with lomustine in the treatment of recurrent intracranial
glioblastoma. J Clin Oncol. 2010;28:1168-1174.
28. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor
receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl
Cancer Inst. 2005;97:880-887.
29. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II
trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma:
EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268-1274.